![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Chiron Drug Enters Trials With Global Alliance for TB Drug Development
Chiron Drug Enters Trials With Global Alliance for TB Drug Development
June 14, 2005
Chiron has announced that the Global Alliance for TB Drug Development (TB Alliance) has initiated Phase I clinical trials for the tuberculosis (TB) drug candidate PA-824.
Chiron granted the TB Alliance exclusive worldwide rights to PA-824 and related compounds in 2002, with a commitment to make the TB technology available royalty-free in endemic countries. Clinical trials are scheduled to begin this month. The TB Alliance is a public-private partnership developing affordable, new drug regimens for TB, and PA-824 is the first TB drug from the TB Alliance pipeline to enter clinical study.
After licensing PA-824 from Chiron, the TB Alliance directed and funded the drug's preclinical development. The NIH's National Institute of Allergy and Infectious Diseases also provided in-kind support and technical assistance. More than 40 years have elapsed since the last novel compound was introduced for the treatment of TB, Chiron said.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct